MGMT and alpha thalassemia-X-linked intellectual disability syndrome: Other genetic alterations, not required for diagnosis, are currently investigated in clinics to predict the response to treatment: ATRX (alpha thalassemia/mental retardation syndrome X-linked), TERT (telomerase reverse transcriptase), EGFR (epidermal growth factor receptor), BRAF (V-raf murine sarcoma viral oncogene homolog B1), histone H3K27M mutations and MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation (Table 2) [9].